Sean M. Clayton - Mar 1, 2023 Form 4 Insider Report for Horizon Therapeutics Public Ltd Co (HZNP)

Role
EVP, General Counsel
Signature
/s/ Patrick McIlvenny, Attorney-in-Fact
Stock symbol
HZNP
Transactions as of
Mar 1, 2023
Transactions value $
-$775,911
Form type
4
Date filed
3/6/2023, 03:52 PM
Previous filing
Jan 6, 2023
Next filing
Oct 6, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HZNP Ordinary Shares Options Exercise +14.1K +5064.16% 14.4K Mar 1, 2023 Direct F1, F2
transaction HZNP Ordinary Shares Tax liability -$776K -7.03K -48.81% $110.34 7.38K Mar 1, 2023 Direct
holding HZNP Ordinary Shares 745 Mar 1, 2023 See footnote F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HZNP Restricted Stock Units Options Exercise $0 +14.1K +100% $0.00 28.3K Mar 1, 2023 Ordinary shares 14.1K Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer.
F2 Includes 279 ordinary shares of the Issuer acquired by the reporting person on December 1, 2022 pursuant to an employee stock purchase program.
F3 The shares are held by the Clayton Family Trust, of which the Reporting Person is the co-trustee and beneficiary.
F4 The shares subject to the restricted stock units vest 1/3rd annually on each anniversary of March 1, 2022.